|
1
|
Arnold M, Abnet CC, Neale RE, Vignat J,
Giovannucci EL, McGlynn KA and Bray F: Global burden of 5 major
types of gastrointestinal cancer. Gastroenterology.
159:335–349.e15. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Venerito M, Link A, Rokkas T and
Malfertheiner P: Review: Gastric cancer-Clinical aspects.
Helicobacter. 24 (Suppl 1):e126432019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xu J, Zhang Y, Jia R, Yue C, Chang L, Liu
R, Zhang G, Zhao C, Zhang Y, Chen C, et al: Anti-PD-1 antibody
SHR-1210 combined with apatinib for advanced hepatocellular
carcinoma, gastric, or esophagogastric junction cancer: An
open-label, dose escalation and expansion study. Clin Cancer Res.
25:515–523. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Doi T, Shitara K, Naito Y, Shimomura A,
Fujiwara Y, Yonemori K, Shimizu C, Shimoi T, Kuboki Y, Matsubara N,
et al: Safety, pharmacokinetics, and antitumour activity of
trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug
conjugate, in patients with advanced breast and gastric or
gastro-oesophageal tumours: A phase 1 dose-escalation study. Lancet
Oncol. 18:1512–1522. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bando H, Doi T, Muro K, Yasui H, Nishina
T, Yamaguchi K, Takahashi S, Nomura S, Kuno H, Shitara K, et al: A
multicenter phase II study of TAS-102 monotherapy in patients with
pre-treated advanced gastric cancer (EPOC1201). Eur J Cancer.
62:46–53. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shitara K, Bang YJ, Iwasa S, Sugimoto N,
Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, et al:
Trastuzumab deruxtecan in previously treated HER2-positive gastric
cancer. N Engl J Med. 382:2419–2430. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sun X, Yang S, Feng X, Zheng Y, Zhou J,
Wang H, Zhang Y, Sun H and He C: The modification of ferroptosis
and abnormal lipometabolism through overexpression and knockdown of
potential prognostic biomarker perilipin2 in gastric carcinoma.
Gastric Cancer. 23:241–259. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang Q, Lu P, Wang T, Zheng Q, Li Y, Leng
SX, Meng X, Wang B, Xie J and Zhang H: Sitagliptin affects gastric
cancer cells proliferation by suppressing Melanoma-associated
antigen-A3 expression through Yes-associated protein inactivation.
Cancer Med. 9:3816–3828. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guo HL, Zhang C, Liu Q, Li Q, Lian G, Wu
D, Li X, Zhang W, Shen Y, Ye Z, et al: The Axin/TNKS complex
interacts with KIF3A and is required for insulin-stimulated GLUT4
translocation. Cell Res. 22:1246–1257. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang J, Qu Q, Guo Y, Xiang Y and Feng D:
Tankyrases/β-catenin signaling pathway as an anti-proliferation and
anti-metastatic target in hepatocarcinoma cell lines. J Cancer.
11:432–440. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Y, Liu S, Mickanin C, Feng Y,
Charlat O, Michaud GA, Schirle M, Shi X, Hild M, Bauer A, et al:
RNF146 is a poly(ADP-ribose)-directed E3 ligase that regulates axin
degradation and Wnt signalling. Nat Cell Biol. 13:623–629. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ozaki Y, Matsui H, Asou H, Nagamachi A,
Aki D, Honda H, Yasunaga S, Takihara Y, Yamamoto T, Izumi S, et al:
Poly-ADP ribosylation of Miki by tankyrase-1 promotes centrosome
maturation. Mol Cell. 47:694–706. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chi NW and Lodish HF: Tankyrase is a
golgi-associated mitogen-activated protein kinase substrate that
interacts with IRAP in GLUT4 vesicles. J Biol Chem.
275:38437–38444. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cook BD, Dynek JN, Chang W, Shostak G and
Smith S: Role for the related poly(ADP-Ribose) polymerases
tankyrase 1 and 2 at human telomeres. Mol Cell Biol. 22:332–342.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pai SG, Carneiro BA, Mota JM, Costa R,
Leite CA, Barroso-Sousa R, Kaplan JB, Chae YK and Giles FJ:
Wnt/beta-catenin pathway: Modulating anticancer immune response. J
Hematol Oncol. 10:1012017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gao J, Zhang J, Long Y, Tian Y and Lu X:
Expression of tankyrase 1 in gastric cancer and its correlation
with telomerase activity. Pathol Oncol Res. 17:685–690. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yue B, Song C, Yang L, Cui R, Cheng X,
Zhang Z and Zhao G: METTL3-mediated N6-methyladenosine modification
is critical for epithelial-mesenchymal transition and metastasis of
gastric cancer. Mol Cancer. 18:1422019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bure IV, Nemtsova MV and Zaletaev DV:
Roles of E-cadherin and noncoding RNAs in the
epithelial-mesenchymal transition and progression in gastric
cancer. Int J Mol Sci. 20:2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ji L, Zhang B and Zhao G: Liver X receptor
α (LXRα) promoted invasion and EMT of gastric cancer cells by
regulation of NF-κB activity. Hum Cell. 30:124–132. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhu X, Chen L, Liu L and Niu X:
EMT-mediated acquired EGFR-TKI resistance in NSCLC: Mechanisms and
strategies. Front Oncol. 9:10442019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li S, Cong X, Gao H, Lan X, Li Z, Wang W,
Song S, Wang Y, Li C, Zhang H, et al: Tumor-associated neutrophils
induce EMT by IL-17a to promote migration and invasion in gastric
cancer cells. J Exp Clin Cancer Res. 38:62019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wei Y, Zhang F, Zhang T, Zhang Y, Chen H,
Wang F and Li Y: LDLRAD2 overexpression predicts poor prognosis and
promotes metastasis by activating Wnt/β-catenin/EMT signaling
cascade in gastric cancer. Aging (Albany NY). 11:8951–8968. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li G, Su Q, Liu H, Wang D, Zhang W, Lu Z,
Chen Y, Huang X, Li W, Zhang C, et al: Frizzled7 promotes
epithelial-to-mesenchymal transition and stemness via activating
canonical Wnt/β-catenin pathway in gastric cancer. Int J Biol Sci.
14:280–293. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang S, Yin J, Chen D, Nie F, Song X, Fei
C, Miao H, Jing C, Ma W, Wang L, et al: Small-molecule modulation
of Wnt signaling via modulating the Axin-LRP5/6 interaction. Nat
Chem Biol. 9:579–585. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Luo H, Vong CT, Chen H, Gao Y, Lyu P, Qiu
L, Zhao M, Liu Q, Cheng Z, Zou J, et al: Naturally occurring
anti-cancer compounds: Shining from Chinese herbal medicine. Chin
Med. 14:482019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fan HN, Zhu MY, Peng SQ, Zhu JS, Zhang J
and Qu GQ: Dihydroartemisinin inhibits the growth and invasion of
gastric cancer cells by regulating cyclin D1-CDK4-Rb signaling.
Pathol Res Pract. 216:1527952020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Su T, Li F, Guan J, Liu L, Huang P, Wang
Y, Qi X, Liu Z, Lu L and Wang D: Artemisinin and its derivatives
prevent Helicobacter pylori-induced gastric carcinogenesis
via inhibition of NF-κB signaling. Phytomedicine. 63:1529682019.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
In H, Solsky I, Palis B, Langdon-Embry M,
Ajani J and Sano T: Validation of the 8th edition of the AJCC TNM
staging system for gastric cancer using the national cancer
database. Ann Surg Oncol. 24:3683–3691. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhao W, Deng C, Han Q, Xu H and Chen Y:
Carvacrol may alleviate vascular inflammation in diabetic db/db
mice. Int J Mol Med. 46:977–988. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu J, Huang C, Peng C, Xu F, Li Y, Yutaka
Y, Xiong B and Yang X: Stromal fibroblast activation protein alpha
promotes gastric cancer progression via epithelial-mesenchymal
transition through Wnt/β-catenin pathway. BMC Cancer. 18:10992018.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Guo X, Zhang L, Fan Y, Zhang D, Qin L,
Dong S and Li G: Oxysterol-binding protein-related protein 8
inhibits gastric cancer growth through induction of er stress,
inhibition of wnt signaling, and activation of apoptosis. Oncol
Res. 25:799–808. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mazzoni SM and Fearon ER: AXIN1 and AXIN2
variants in gastrointestinal cancers. Cancer Lett. 355:1–8. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu AN, Zhu ZH, Chang SJ and Hang XS:
Twist expression associated with the epithelial-mesenchymal
transition in gastric cancer. Mol Cell Biochem. 367:195–203. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang T, Hou J, Jian S, Luo Q, Wei J, Li Z,
Wang X, Bai P, Duan B, Xing J and Cai J: miR-29b negatively
regulates MMP2 to impact gastric cancer development by suppress
gastric cancer cell migration and tumor growth. J Cancer.
9:3776–3786. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jiang XJ, Lin J, Cai QH, Zhao JF and Zhang
HJ: CDH17 alters MMP-2 expression via canonical NF-κB signalling in
human gastric cancer. Gene. 682:92–100. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ni YJ, Lu J and Zhou HM: Propofol
suppresses proliferation, migration and invasion of gastric cancer
cells via regulating miR-29/MMP-2 axis. Eur Rev Med Pharmacol Sci.
23:8606–8615. 2019.PubMed/NCBI
|
|
38
|
Zhao L, Niu H, Liu Y, Wang L, Zhang N,
Zhang G, Liu R and Han M: LOX inhibition downregulates MMP-2 and
MMP-9 in gastric cancer tissues and cells. J Cancer. 10:6481–6490.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ju RJ, Cheng L, Peng XM, Wang T, Li CQ,
Song XL, Liu S, Chao JP and Li XT: Octreotide-modified liposomes
containing daunorubicin and dihydroartemisinin for treatment of
invasive breast cancer. Artif Cells Nanomed Biotechnol. 46 (Suppl
1):616–628. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen X, He LY, Lai S and He Y:
Dihydroartemisinin inhibits the migration of esophageal cancer
cells by inducing autophagy. Oncol Lett. 20:942020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hui HY, Wu N, Wu M, Liu Y, Xiao SX and
Zhang MF: Dihydroartemisinin suppresses growth of squamous cell
carcinoma A431 cells by targeting the Wnt/β-catenin pathway.
Anticancer Drugs. 27:99–105. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Solberg NT, Waaler J, Lund K, Mygland L,
Olsen PA and Krauss S: TANKYRASE inhibition enhances the
antiproliferative effect of PI3K and EGFR inhibition, mutually
affecting β-CATENIN and AKT signaling in colorectal cancer. Mol
Cancer Res. 16:543–553. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yang HY, Shen JX, Wang Y, Liu Y, Shen DY
and Quan S: Tankyrase promotes aerobic glycolysis and proliferation
of ovarian cancer through activation of Wnt/β-catenin signaling.
Biomed Res Int. 2019:26863402019.PubMed/NCBI
|
|
44
|
Ma Z, Han C, Xia W, Wang S, Li X, Fang P,
Yin R, Xu L and Yang L: circ5615 functions as a ceRNA to promote
colorectal cancer progression by upregulating TNKS. Cell Death Dis.
11:3562020. View Article : Google Scholar : PubMed/NCBI
|
